Dr. Nayak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-2166Fax+1 617-632-4773
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2006 - 2009
New York Downtown HospitalResidency, Internal Medicine, 2004 - 2006
Grant Medical CollegeClass of 2002
Certifications & Licensure
FL State Medical License 2022 - Present
ME State Medical License Current
MA State Medical License 2011 - 2026
NY State Medical License 2011 - 2013
PA State Medical License 2009 - 2010- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
- Pembrolizumab, Ibrutinib and Rituximab in PCNSL Start of enrollment: 2020 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 56 citationsClinical trial links oncolytic immunoactivation to survival in glioblastoma.Alexander L Ling, Isaac H Solomon, Ana Montalvo Landivar, Hiroshi Nakashima, Jared K Woods
Nature. 2023-11-01 - 763 citationsEpidemiology of Brain MetastasesLakshmi Nayak, Eudocia Q. Lee, Patrick Y. Wen
Current Oncology Reports. 2012-02-01 - 291 citationsBrain metastases.Achal Singh Achrol, Robert C Rennert, Carey Anders, Riccardo Soffietti, Manmeet S Ahluwalia
Nature Reviews. Disease Primers. 2019-01-17
Lectures
- Turning the Corner in Relapsed/Refractory CNS Lymphoma: Applying Precision and Immune-Based...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with r...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Kazia Enters Clinical Collaboration with Dana-Farber Cancer Institute for Primary CNS LymphomaSeptember 22nd, 2020
The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in FundingNovember 8th, 2018
Immunotherapy Agent Yields Full and Partial Remissions in Aggressive Non-Hodgkin LymphomasDecember 5th, 2016- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
